Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning.
Grimley, M; Asnani, M; Shrestha, A; Felker, S; Lutzko, C; Arumugam, PI; Witting, S; Knight-Madden, J; Niss, O; Quinn, CT; et al.
Blood.
2021;
138:3970-3970.
Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response.
Sadaf, A; Quinn, CT; Korpik, JB; Pfeiffer, A; Reynaud, M; Niss, O; Malik, P; Ware, RE; Kalfa, TA; McGann, PT.
Blood Cells, Molecules, and Diseases.
2021;
90.
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al.
British Journal of Haematology.
2021;
194:617-625.
Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT.
Pediatric Blood and Cancer.
2021;
68.
Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
Karkoska, K; Quinn, CT; Niss, O; Pfeiffer, A; Dong, M; Vinks, AA; McGann, PT.
American Journal of Hematology.
2021;
96:538-544.
Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).
Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al.
Blood Cells, Molecules, and Diseases.
2021;
87.
Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity.
Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al.
Scientific Reports.
2020;
10.
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
Meier, ER; Creary, SE; Heeney, MM; Dong, M; Appiah-Kubi, AO; Nelson, SC; Niss, O; Piccone, C; Quarmyne, MO; Quinn, CT; et al.
Trials.
2020;
21.
Reversible Myelofibrosis in Pediatric Renal Osteodystrophy.
Sabulski, A; Hughley, E; Nehus, EJ; Grier, DD; Niss, O.
Journal of Pediatrics.
2020;
226:303-305.
Lymphopenia in adults after the Fontan operation: prevalence and associations.
Alsaied, T; Possner, M; Brown, N; Almeneisi, H; Szugye, C; Trout, AT; Niss, O; Palermo, JJ; Zafar, F; Dillman, JR; et al.
Cardiology in the Young.
2020;
30:641-648.